Another research group revealed that reduced ACE2 expression via RNA interference promotes the proliferation of cultured pancreatic cancer cells, suggesting that the inhibition of ACE2 may have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma and the reduction of cell proliferation (Zhou et al., 2009, 2011). The gene discussed is ACE2; the disease is familial pancreatic carcinoma.